Titre : | To prohibit or regulate psychoactive substances: has New Zealand got the right approach? (2017) |
Auteurs : | S. B. RIZWAN ; A. J. VERNALL |
Type de document : | Article : Périodique |
Dans : | British Medical Journal (Vol.356, n°8098, 25 March 2017) |
Article en page(s) : | j1195 |
Langues: | Anglais |
Discipline : | SAN (Santé publique / Public health) |
Mots-clés : |
Thésaurus géographique NOUVELLE ZELANDEThésaurus mots-clés POLITIQUE ; PRODUIT ILLICITE ; PROHIBITION ; DROGUES DE SYNTHESE ; REGLEMENTATION ; SANTE PUBLIQUE ; SECURITE SANITAIRE ; RECHERCHE |
Résumé : |
Prohibition of a continuous stream of new psychoactive substances is both difficult and costly. Shakila Rizwan and Andrea Vernall look at New Zealand's attempt to regulate instead.
Many countries are experiencing a surge in the recreational use of new psychoactive substances. The most common approach to this problem is to prohibit known or broadly defined chemical classes. However, this has been difficult to implement, particularly as manufacturers rapidly develop new substances to replace prohibited compounds. The New Zealand government decided to adopt a different approach, creating a pre-market approval regulatory system for new psychoactive substances, the Psychoactive Substances Act 2013. The United Kingdom recently introduced similar regulatory legislation, the Psychoactive Substances Act 2016. Here we discuss some of the controversies surrounding the New Zealand act and the international implications. [Extract] |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 32 |
Affiliation : | School of Pharmacy, University of Otago, Dunedin, New Zealand |
Accueil